Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Profit After Tax (2022 - 2025)

Historic Profit After Tax for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to -$32.7 million.

  • Taysha Gene Therapies' Profit After Tax fell 2824.4% to -$32.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$99.9 million, marking a year-over-year decrease of 33882.4%. This contributed to the annual value of -$89.3 million for FY2024, which is 1995.95% up from last year.
  • Latest data reveals that Taysha Gene Therapies reported Profit After Tax of -$32.7 million as of Q3 2025, which was down 2824.4% from -$26.9 million recorded in Q2 2025.
  • Taysha Gene Therapies' 5-year Profit After Tax high stood at $47.7 million for Q4 2023, and its period low was -$117.1 million during Q3 2023.
  • Moreover, its 4-year median value for Profit After Tax was -$25.5 million (2024), whereas its average is -$29.9 million.
  • Data for Taysha Gene Therapies' Profit After Tax shows a peak YoY increase of 18667.89% (in 2023) and a maximum YoY decrease of 34138.8% (in 2023) over the last 5 years.
  • Over the past 4 years, Taysha Gene Therapies' Profit After Tax (Quarter) stood at -$55.1 million in 2022, then soared by 186.68% to $47.7 million in 2023, then plummeted by 139.35% to -$18.8 million in 2024, then crashed by 74.25% to -$32.7 million in 2025.
  • Its Profit After Tax was -$32.7 million in Q3 2025, compared to -$26.9 million in Q2 2025 and -$21.5 million in Q1 2025.